Connect Sign In
Hepatitis B Virus Genotype by Sequencing
Ordering Recommendation
Determine antiviral drug resistance by DNA sequencing.
New York DOH Approval Status
Specimen Required
Lavender (EDTA), pink (K2EDTA), serum separator tube, or plasma preparation tube.
Separate serum or plasma from cells within 24 hours. Transfer 2 mL serum or plasma to an ARUP standard transport tube. (Min: 0.5 mL)
Frozen.
Heparinized specimens.
Ambient: 72 hours; Refrigerated: 1 week; Frozen: 6 weeks
Methodology
Polymerase Chain Reaction (PCR) / Sequencing
Performed
Tue, Fri
Reported
7-10 days
Reference Interval
Interpretive Data
HBV Genotype by Sequencing is determined by sequencing both the HBV reverse transcriptase (RT) polymerase and the hepatitis B surface antigen (HBsAg) encoding regions. Detected resistance mutations in the RT region and mutations in HBsAg region are reported, along with identification of major HBV genotypes. Mutations present in viral subpopulations below 20 percent of total may not be detected.
A result of Sensitive, Resistant, or Reduced Sensitivity is based on available clinical practice guidelines. A result of Possible Resistance indicates evidence in the clinical literature suggestive of resistance that has not been integrated into current guidelines.
Laboratory Developed Test (LDT)
Note
This test may be unsuccessful if the HBV viral load is less than log 3.0 or 1,000 IU/mL of plasma.
Hotline History
CPT Codes
87912
Components
| Component Test Code* | Component Chart Name | LOINC |
|---|---|---|
| 2001568 | HBV Surface Antigen Mutations by Seq | |
| 2001569 | Hepatitis B Genotype by Seq | 104995-6 |
| 2001570 | HBV RT Polymerase Mutations by Seq |
Aliases
- Adefovir
- Entecavir
- HBsAg mutations
- HBV drug resistance testing
- HBV Genotype
- HBV Genotyping
- HBV Resistance
- HBV Resistance Sequencing
- HBV Sequencing
- Hepatitis B Drug Resistance Panel
- Lamivudine
- Telbivudine
- Tenofovir
